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The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500mgm
 2, epirubicin
100mgm
 2 and cyclophosphamide 500mgm
 2, six cycles every 21 days), to an epirubicin–vinorelbine (Epi-Vnr) combination for
early, poor-prognosis breast cancer patients. Patients (482) were randomised to receive FEC100, or Epi-Vnr (epirubicin 50mgm
 2
day 1 and vinorelbine 25mgm
 2, days 1 and 8, six cycles every 21 days). The 7-year disease-free survival rates were 59.4 and 58.8%,
respectively (P¼0.47). The relative dose intensity of planned epirubicin doses was 89.1% with FEC100 and 88.9% with Epi-Vnr.
There were significantly more grades 3–4 neutropenia (P¼0.009) with Epi-Vnr, and significantly more nausea-vomiting (Po0.0001),
stomatitis (P¼0.0007) and alopecia (Po0.0001) with FEC100. No cases of congestive heart failure were reported, whereas four
decreases in left ventricular ejection fraction occurred after FEC100 and five after Epi-Vnr. One case of acute myeloblastic leukaemia
was registered in the FEC100 arm. After 7 years of follow-up, there was no difference between treatment arms. Epi-Vnr regimen
provided a good efficacy in such poor-prognosis breast cancer patients, and could be an alternative to FEC100, taking into account
respective safety profiles of both regimens.
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Successive overviews by the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) have well established the benefit
of adjuvant chemotherapy in node-positive breast cancer patients
irrespective of age as well as the pivotal role of anthracycline-based
chemotherapy, which significantly reduced annual rates of relapse
and death compared with the combination of cyclophosphamide,
methotrexate and fluorouracil (Early Breast Cancer Trialists’
Collaborative Group (EBCTCG), 2005). After 10 years of follow-
up, the French Adjuvant Study Group (FASG)-05 trial has showed
previously that six cycles of FEC100 (fluorouracil 500mgm
 2,
epirubicin 100mgm
 2 and cyclophosphamide 500mg
 2) signifi-
cantly improved disease-free survival (DFS) and overall survival
(OS) compared with FEC50 (same regimen with epirubicin
50mgm
 2), in poor-prognosis, node-positive breast cancer
patients (Bonneterre et al, 2005). On the basis of results of
FASG-05 trial, the FEC100 regimen was considered one of the
reference treatments for node-positive breast cancer.
In first-line metastatic breast cancer treatment, single-agent
therapy with vinorelbine has shown overall response rates varying
from 35 to 60% with a good clinical tolerance (Canobbio et al,
1989; Fumoleau et al, 1993; Garcı ´a-Conde et al, 1994; Weber et al,
1995). Thereby, it was logical to combine vinorelbine and
anthracycline to evaluate their activity in advanced breast cancer.
Impressive results have been obtained through an every 3-week
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sschedule of vinorelbine 25mgm
 2, days 1 and 8, plus doxorubicin
50mgm
 2 on day 1, producing an objective response rate of 74%
(complete response 21%) and a median survival time of 27.5
months (Spielmann et al, 1994), but at the price of a high level of
cardiac toxicity as 10% of patients experienced grades 2–4
treatment-related cardiotoxicity. In a phase III trial, comparing
vinorelbine–doxorubicin and FAC (fluorouracil 500mgm
 2,
doxorubicin 50mgm
 2 and cyclophosphamide 50mg
 2), the
efficacy of both regimens was similar, whereas vinorelbine–
doxorubicin regimen was more active in the subset of patients with
visceral metastatic disease, especially liver involvement (Blajman
et al, 1999). Giving the better safety profile of epirubicin compared
with doxorubicin in terms of haematologic and cardiac toxicities
(Torti et al, 1986; Mouridsen, 1990), and the similar efficacy of
both anthracyclines when used at equimolar doses of 50mgm
 2
(French Epirubicin Study Group, 1988; Italian Multicentre Breast
Study with Epirubicin, 1988), the replacement of doxorubicin by
epirubicin could be of interest. Subsequently, the FASG-05 trial
demonstrated a significant superiority of FEC100 over FEC50
regimen in adjuvant setting (Bonneterre et al, 2005). The use of
FEC100 regimen led to 1% of congestive heart failure (CHF) after
10 years of follow-up, without cardiac death. Thereby, we
considered six cycles of FEC100 as our standard adjuvant
chemotherapy for node-positive breast cancer patients.
In 1993, we initiated a randomised phase III trial, FASG-09, to
compare our reference adjuvant chemotherapy regimen, FEC100,
to an Epi-Vnr combination in poor-prognosis, node-positive early
breast cancer patients. The primary end point was the DFS, and
secondary end points were OS and safety.
PATIENTS AND METHODS
Study population
Women eligible for the study were between 18 and 64 years of age,
and had undergone primary surgery (modified mastectomy or
tumorectomy) plus axillary dissection for unilateral, operable
carcinoma of the breast. Patients had to present with histologically
proven axillary lymph node involvement (at least five nodes
removed), and either more than three positive nodes or one to
three positive nodes plus SBR grade X2 and HR-negative tumour
(estrogen (ER) and progesterone (PgR) receptors). Main eligi-
bility criteria included the World Health Organisation (WHO)
performance status p2, adequate haematologic (granulocyte
count X2 10
9l
 1 and platelets count X100 10
9l
 1), hepatic
(bilirubinp35mmoll
 1) and renal (serum creatinine p130mmoll
 1)
tests, and no cardiac dysfunction (left ventricular ejection fraction
(LVEF) X50%). Patients were excluded from the study if they had
evidence of metastases, documented history of cardiac disease
contraindicating anthracyclines, previous cancer (except treated
basal cell and squamous cell carcinoma of the skin or cancer of the
uterine cervix), previous radiation therapy, hormonotherapy or
chemotherapy for breast cancer or were greater than 42 days from
initial breast cancer surgery.
Potentially eligible patients underwent bone scan, chest X-ray,
abdominal ultrasound or CT scan, and contralateral mammo-
graphy. Patients had a cardiac assessment consisting of an electro-
cardiogram (ECG) and a LVEF measurement at rest by
radioisotopic or echographic methods. Written informed consent
was obtained before randomisation. The protocol was reviewed
and approved by the Ethics Committee/Institutional Review Board,
and the study was conducted according to the Declaration of
Helsinki and French Health Authorities requirements.
Study design
This was a randomised, multicenter and open-label phase III
study. Randomisation procedures were centralized and balanced
per block. Patients were assigned to receive FEC100 (fluorouracil
500mgm
 2, epirubicin 100mgm
 2 and cyclophosphamide
500mgm
 2 intravenously on day 1, every 21 days for six cycles)
or Epi-Vnr (epirubicin 50mgm
 2 intravenously on day 1 and
vinorelbine 25mgm
 2 intravenously on days 1 and 8, every 21
days for six cycles). Stratification was by the number of positive
auxillary nodes (1–3, 4–9 and X10) and centre. Primary
prophylaxis with granulocyte colony-stimulating factors (G-CSF)
and antibiotics was prohibited. Antiemetics were prescribed
routinely before each cycle. The allocated treatment was started
within 42 days after initial surgery. An absolute granulocyte count
o2 10
9l
 1 and/or a platelet count o100 10
9l
 1 on day 21 led
to a treatment delay of at least 1 week. Treatment was stopped if
haematologic recovery took more than 3 weeks beyond day 21. The
epirubicin dose was reduced by 50%, if serum bilirubin levels were
35–50mmoll
 1 and treatment was stopped if bilirubin levels
exceeded 50mmoll
 1.
Tamoxifen (30mgday
 1) was started at the first chemotherapy
cycle and continued for 3 years in postmenopausal women. For
HR-negative patients, treatment with tamoxifen was given at the
investigator’s discretion, but the policy had to be similar for both
arms at each centre. Radiotherapy was initiated within 4 weeks
after the last cycle of chemotherapy and consisted of radiation to
the chest wall, supraclavicular area, internal mammary chain and
auxillary area (in case of pN1 tumour). In patients who had
undergone breast-conserving surgery, a complementary boost was
delivered to the breast. Radiotherapy procedures had to be similar
for both arms at a given centre.
The tolerability of chemotherapy was evaluated before each
cycle, an ECG and an absolute blood count were performed on day
21, and non-haematologic toxicity was evaluated during the period
between cycles. Toxicity was graded according to the WHO
criteria. It was recommended to assess LVEF within 3–4 weeks
after the last chemotherapy cycle. A decrease in LVEF was defined
as an absolute value below 50%, and/or a relative decline of more
than 20% compared with baseline value. Additional assessment of
LVEF was left at the discretion of each investigator. Patients
underwent clinical and biochemical assessments every 6 months
during a 5-year follow-up period, and yearly thereafter. Imaging
studies (mammography, chest X-ray, liver ultrasound and bone
scan) were performed yearly during a 5-year follow-up period and
every 2 years thereafter. Patients were followed until death.
Statistical analysis
The primary end point was the 5-year DFS defined as the time
from randomisation until the first relapse (local, regional and/or
distant). A contralateral breast cancer was considered a new
primary malignancy. This trial was designed to detect a 10%
difference in DFS with a power of 80%, and a two-sided type I error
of 5%. These hypotheses required enroling 460 patients. Data were
analysed according to the intention-to-treat (ITT) principle, using
SPSS software (SPSS Inc., Chicago, IL, USA). Secondary end points
were OS defined as the time from randomisation until death from
any cause and safety. Patients who received at least one dose of
study drug were analysed for safety.
The w
2 test was used to compare baseline categorical variables
and incidence of adverse events between treatment arms.
Continuous variables were compared by using analysis of variance.
The relative dose intensity (RDI) was calculated based on the ratio
of the drug dose actually delivered in the originally expected time
to the expected dose in the expected time. The DFS and OS rates
were calculated by the Kaplan–Meier method, and were compared
using a log-rank test. A multivariate analysis (Cox regression
model) was adjusted for age, menopausal status, surgery, SBR
grade, histological tumour size, number of positive auxillary
lymph nodes and HR status.
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Patient characteristics
Between June 1993 and April 1998, 18 French centres enrolled 482
patients (241 in FEC100 and 241 in Epi-Vnr). Of these women,
seven were lost to follow-up at the time of randomisation and were
censored at this date, and four presented with an initial metastatic
disease. Efficacy analysis involved 471 patients (235 in FEC100 and
236 in Epi-Vnr). The compliance and safety analyses were
performed on 469 treated patients (236 in FEC100 and 233 in
Epi-Vnr). Baseline characteristics were well balanced between
treatment arms (Table 1). However, the exclusive comparison of
ductal and lobular carcinomas exhibited a significant higher rate of
lobular carcinomas in the FEC100 arm (P¼0.03).
Treatment
Among the 469 treated patients, six treatment cycles were
completed by 94.9% of patients in the FEC100 group and by
96.1% of the patients in the Epi-Vnr group (P¼0.36). Twenty-one
patients stopped prematurely the treatment protocol (12 in FEC100
and 9 in Epi-Vnr). Among these treatment interruptions, two
patients died in the FEC100 arm: one from a septic shock and one
from a rhythm disorder related to a hypokaliemia. The remaining
reasons were haematologic toxicity and/or infectious complica-
tions (n¼5), digestive toxicity (n¼6), pulmonary embolism
(n¼2), patient refusal (n¼3), cardiac rhythm disorders (n¼1),
late discovery of initial liver metastases (n¼1) and unknown
reason (n¼1). Treatment compliance and doses are summarised
in Table 2. There were significantly more cycles delayed beyond 24
days in the Epi-Vnr arm (30.7 vs 25.6%, P¼0.0028), and the day 8
infusion of vinorelbine was not delivered in 14 cycles (1%). The
epirubicin RDI was not different between treatment arms
(P¼0.87), although the dose density was twice in the FEC100 arm.
Tamoxifen was prescribed in 87 patients (36.9%) of FEC100
group and in 84 patients (36.1%) of Epi-Vnr group. Among
patients who received tamoxifen, 25 (10.6%) and 31 (13.3%) were
HR-negative, respectively. Three premenopausal patients received
tamoxifen (one in FEC100 and two in Epi-Vnr). Radiotherapy was
delivered in 227 (96.2%) and 229 (98.3%) treated patients,
respectively.
DFS and OS
The median follow-up time from randomisation was 78 months
(range: 2–113). At the cut-off date for analysis, 89 patients (37.9%)
had relapsed in the FEC100 group and 96 (40.7%) in the Epi-Vnr
group (Table 3). The 7-year DFS rates were 59.4% (95% confidence
interval (95% CI), 52.5–66.3%) with FEC100 and 58.8% (95% CI,
52.1–65.5%) (P¼0.47; Table 4 and Figure 1) in Epi-Vnr. The
incidence of local relapse was 8.1 and 10.6%, respectively. There
was no difference in the pattern of recurrences, and the most
common site of relapse was bone (39.3 and 42.7%, respectively). A
plurimetastatic disease was reported in 28.1 and 33.3% of patients,
respectively (P¼0.44). Patients receiving tamoxifen showed
improved DFS rates, irrespective of chemotherapy regimen (64.9
vs 55.7%, P¼0.009). The Cox proportional hazards model showed
that modified mastectomy and histological tumour size 420mm
were independent prognostic factors of relapse, knowing that both
factors were significantly correlated (Table 4). In this model, the
comparison between treatment arms remained not significant.
There were 133 deaths involving 62 patients (26.4%) in the
FEC100 arm and 71 patients (30.1%) in the Epi-Vnr arm (Table 3).
The 7-year OS rates were 71.5% (95% CI, 64.8–78.2%) with
FEC100 and 66.7% (95% CI, 60–73.4%) (P¼0.38) with Epi-Vnr
(Figure 2). All but 16 deaths (eight in FEC100 and eight in Epi-
Vnr) were owing to progression of the disease.
Table 1 Patient and tumour characteristics at baseline
Characteristics n (%)
FEC100
(n¼241)
Epi-Vnr
(n¼241) P-value
Age (years)
Median (range) 50 (24–69) 51 (29–66) 0.61
o40 35 (14.5) 29 (12.0) 0.42
X40 206 (85.5) 212 (88.0)
Menopausal status
Premenopausal 115 (47.7) 117 (48.5) 0.85
Postmenopausal 126 (52.3) 124 (51.5)
Surgery
Tumorectomy 144 (59.8) 156 (64.7) 0.34
Mastectomy 96 (39.8) 85 (35.3)
Unknown 1 (0.4) 0
Histology
Ductal 189 (78.4) 199 (82.6) 0.08
Lobular 32 (13.3) 17 (7.1)
Other 13 (5.4) 12 (5.0)
Unknown 7 (2.9) 13 (5.4)
SBR grade
1 17 (7.1) 14 (5.8) 0.33
2 92 (38.2) 90 (37.3)
3 117 (48.5) 111 (46.1)
Unknown/not gradable 15 (6.2) 26 (10.8)
Histological tumour size (mm)
p20 83 (34.4) 93 (38.6) 0.64
420 132 (54.8) 123 (51.0)
Unknown 26 (10.8) 25 (10.4)
Axillary lymph node involvement
1–3 56 (23.2) 63 (26.1) 0.46
43 185 (76.8) 178 (73.9)
Hormone-receptor status
Positive (ER and/or PgR) 79 (32.8) 97 (40.2) 0.15
Negative (ER and PR) 152 (63.1) 131 (54.4)
Unknown 10 (4.1) 13 (5.4)
Epi-Vnr¼epirubicin–vinorelbine; ER¼estrogen receptors; PgR¼progesterone
receptors; SBR¼Scarff, Bloom and Richardson.
Table 2 Treatment characteristics
Characteristics FEC100 Epi-Vnr
Treated patients (n) 236 233
Cycles delivered (n) 1386 1373
Six cycles completed, no. of treated
patients (%)
224 (94.9) 224 (96.1)
Treatement delayed, no. of cycles (%) 355 (25.6) 422 (30.7)
Cumulative dose, median (range)
Epirubicin 600 (100–628) 300 (97–379)
Vinorelbine NA 300 (51–387)
Mean relative dose intensity, % (s.d.)
Epirubicin 89.1 (11.8) 88.9 (10.2)
Vinorelbine NA 87.8 (11.2)
Mean dose intensity, mgm
 2week
 1 (s.d.)
Epirubicin 29.9 (3.9) 15.1 (1.5)
Vinorelbine NA 14.9 (1.7)
Epi-Vnr¼epirubicin–vinorelbine; NA¼not applicable; s.d.¼standard deviation.
Epirubicin–vinorelbine in early breast cancer
P Kerbrat et al
1635
British Journal of Cancer (2007) 96(11), 1633–1638 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sAcute and delayed toxicities
Toxicity was evaluated in 469 patients according to the WHO
criteria. Adverse events experienced per patient are described in
Table 5. The incidence of grades 3–4 neutropenia on day 21 was
more frequent with Epi-Vnr (P¼0.009). Although no significant
difference was observed in terms of infection, one patient died
from a septic shock in the FEC100 arm secondary to a poorly
monitored febrile neutropenia at home. One case of grade 1
thrombocytopenia occurred with FEC100 and one case of grade 2
with Epi-Vnr. There were significantly more nausea-vomiting,
stomatitis and alopecia with FEC100.
During chemotherapy, 20 cardiac abnormalities were diagnosed
(10 in FEC100 and 10 in Epi-Vnr). Among these 20 cases, one
consisted of a decrease in LVEF below 50% (Epi-Vnr arm). The
other cases were rhythm disorders, of which one patient died
secondary to a hypokaliemia.
After FEC100, in free of disease patients during the follow-up
period, two patients developed a decrease in LVEF below 50%, one
died from a mitral insufficiency and one had T-wave abnormalities
Table 3 Summary of events in patients entered in the efficacy analysis
Events n (%) FEC100 (n¼235) Epi-Vnr (n¼236)
First event 105 (44.7) 110 (46.6)
Relapse 87 (37.0) 95 (40.2)
Local only 13 (5.5) 17 (7.2)
Distant (with or without local) 74 (31.5) 78 (33.0)
Contralateral breast cancer 10 (4.2) 5 (2.1)
Second cancer 5 (2.1) 5 (2.1)
Death 3 (1.3) 5 (2.1)
Any event
Relapse 89 (37.9) 96 (40.7)
Local only 10 (4.2) 9 (3.8)
Local then distant 4 (1.7) 8 (3.4)
Local and distant simultaneously 5 (2.1) 8 (3.4)
Distant only 70 (29.8) 71 (30.1)
Contralateral breast cancer 10 (4.2) 10 (4.2)
Second cancer 8 (3.4) 5 (2.1)
Any death 62 (26.4) 71 (30.1)
Of breast cancer 54 (23.0) 63 (26.7)
Of second cancer 3 (1.3) 0
Due to toxic effects 1 (0.4) 0
Due to cardiac events 2 (0.8) 1 (0.4)
Other causes 2 (0.8)
a 7 (3.0)
b
Epi-Vnr¼epirubicin–vinorelbine.
aNecrotic enteritis (n¼1), unknown (n¼1).
bCirrhosis (n¼1), unknown (n¼6).
Table 4 Prognostic factors of relapse
Univariate analysis Multivariate analysis
Prognostic factors HR (95% CI) P-value HR (95% CI) P-value
Chemotherapy
FEC100 0.90 (0.61–1.19) 0.47 0.91 (0.58–1.24) 0.57
Epi-Vnr 1 1
Tamoxifen
No 1.52 (1.21–1.83) 0.009 1.34 (0.82–1.86) 0.26
Yes 1 1
Age (years)
o40 1.58 (1.20–1.96) 0.01 1.41 (0.91–1.91) 0.17
X40 1 1
Menopausal status
Premenopausal 1.48 (1.19–1.77) 0.008 1.15 (0.63–1.67) 0.59
Postmenopausal 1 1
Surgery
Tumorectomy 0.76 (0.47–1.05) 0.06 0.68 (0.32–1.04) 0.04
Mastectomy 1 1
SBR grade 0.07 0.21
1 0.55 (0.00–1.23) 0.56 (0.00–1.31)
2 0.75 (0.43–1.07) 0.79 (0.42–1.16)
31 1
Histological tumour size (mm)
p20 0.66 (0.34–0.98) 0.01 0.68 (0.31–1.05) 0.04
420 1 1
Lymph node involvement
1–3 0.65 (0.29–0.99) 0.02 0.84 (0.29–1.39) 0.52
431 1
HR status
Negative 0.89 (0.58–1.20) 0.45 0.92 (0.47–1.37) 0.73
Positive 1 1
95% CI¼95% confidence interval; Epi-Vnr¼epirubicin–vinorelbine; HR¼hazard
ratio; HR¼hormone receptors; SBR¼Scarff, Bloom and Richardson.
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Figure 1 Disease-free survival curves.
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Figure 2 Overall survival curves.
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decrease in LVEF below 50% and one developed a cardiomyo-
pathy. In patients who relapsed, two had a decrease in LVEF
consecutively to a first-line chemotherapy with epirubicin
(cumulative dose, 200mgm
 2) and mitoxantrone (cumulative
dose, 39mgm
 2). Both patients had received FEC100 as adjuvant
chemotherapy. Overall, no cases of CHF were reported.
Second malignancies
Twenty patients developed a contralateral breast cancer (10 in
FEC100 and 10 in Epi-Vnr; Table 3). Thirteen patients developed a
second cancer (eight in FEC100 and five in Epi-Vnr; Table 3). One
case of acute myeloblastic leukaemia FAB 4 with del(16q) has
occurred 81 months after receiving FEC100, and 1 year after the
initiation of a hormonotherapy for bone progression. This patient
was still alive at the last contact date. Remaining cases were
chronic lymphocytic leukaemia (n¼1), endometrial carcinoma
(n¼1), uterine cervix carcinoma (n¼2), colorectal cancer (n¼5),
sarcoma (n¼1), head and neck carcinoma (n¼1), and basal cell
carcinoma of skin (n¼1).
DISCUSSION
Our results demonstrated an absence of difference between FEC100
and Epi-Vnr regimens for both DFS and OS in poor-prognosis and
node-positive breast cancer. These results are slightly different
from our initial report presented after 5 years of follow-up, in
which a trend in a better DFS with FEC100 regimen was reported,
providing 5-year DFS rates of 70.9 vs 63.8% with Epi-Vnr (P¼0.07;
Kerbrat et al, 2002). This observation of a decrease in the efficacy
of FEC100 during the course of time has been also highlighted in
the FASG-05 trial, as absolute differences between FEC50 and
FEC100 regimens were 11.5% after 5 years of follow-up and 5.4%
after 10 years (French Adjuvant Study Group, 2001; Bonneterre
et al, 2005). This could mean that the efficacy of FEC100 regimen is
greater within first years following the onset of adjuvant
chemotherapy. Moreover, the design of the present trial, with a
power of 80%, was by definition insufficient to detect a difference
between treatment arms.
One could argue that our schedule of tamoxifen 30mgday
 1 for
3 years given in postmenopausal women does not square to the
current standard of care for tamoxifen. We have to consider that
this trial was initiated at the beginning of 1993. At this period, the
benefit of tamoxifen in premenopausal, hormone-receptor-positive
patients was not established. This has been clearly demonstrated in
the EBCTCG overview presented in 1995 and published in 1998
(Early Breast Cancer Trialists’ Collaborative Group (EBCTCG),
1998). Since 1995, the duration of tamoxifen treatment was
extended to 5 years because of the EBCTCG overview results. This
overview concluded that 5 years was better than 1 or 2 years (Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG), 1998). To
date, no data allows to conclude to the inferiority of 3 or 4 years,
and to provide a difference between 20 and 30mgday
 1 of
tamoxifen. Nevertheless, patients treated in the FASG-09 trial
received similar tamoxifen therapy, which did not modify our
conclusions.
The compliance to chemotherapy was similar between both
arms. Noteworthy, the RDI of epirubicin was 89.1% with FEC100
and 88.9% with Epi-Vnr, in which epirubicin was administered at
50mgm
 2. The epirubicin RDI observed with FEC100 was close to
the 91% RDI reported in the FASG-05 trial (Bonneterre et al, 2005).
On the contrary, the RDI of epirubicin 50mgm
 2 in the Epi-Vnr
regimen was lower than those of 94% previously reported using six
cycles of FEC50 in the FASG-05 trial (Bonneterre et al, 2005). The
additive haematologic toxicity of epirubicin combined with
vinorelbine was probably the main explanation of this decrease
in RDI. Indeed, Epi-Vnr regimen led to a significant increase in
grades 3–4 neutropenia on day 21 compared with FEC100 (24.0 vs
17.4%; P¼0.009), resulting in a greater delay between chemo-
therapy cycles. On the other hand, non-haematologic toxicities
(nausea-vomiting, stomatitis and alopecia) were significantly lower
with Epi-Vnr regimen than with FEC100. There were two deaths in
the FEC100 arm during chemotherapy related to a poorly
monitored septic shock and to a hypokaliemia resulting in major
cardiac dysrhythmia. On the basis of our experience of FEC100
regimen, these fatal events remain rare in the regular use of this
chemotherapy. Cardiac toxicities were not different between
treatment arms. The number of cardiac events was identical and
the incidence of decrease in LVEF during the follow-up period was
0.8 and 2.1%, respectively, without any development of subsequent
cardiac complications or CHF. These results confirmed observa-
tions reported from our whole FASG database, which showed that
the use of epirubicin-based adjuvant chemotherapy was associated
with a low risk of left ventricular dysfunctions ([Fumoleau et al,
2006). When epirubicin was delivered within recommended doses,
a favourable benefit/risk ratio was maintained.
Vinorelbine has a common target with taxanes, interfering with
tubuline. However, the main difference in this mechanism is that
vinorelbine inhibits the connection of microtubules, whereas
taxanes promote the formation of microtubules and stabilise
them. We have showed previously that a concomitant taxane–
anthracycline regimen (TAC: docetaxel, doxorubicin and cyclo-
phosphamide) did not provide different outcomes from FEC100 in
a side-by-side comparison involving node-positive (more than
three positive auxillary lymph nodes) breast cancer patients
(Fumoleau et al, 2003). Results of the present study confirmed
the similar efficacy between FEC100 and a regimen including an
anthracyline delivered concomitantly with a drug interfering with
Table 5 Haematologic and non-haematologic adverse events per
treated patient
Adverse events n (%)
FEC100
(n¼236)
Epi-Vnr
(n¼233) P-value
Neutropenia on day 21
Grades 1–2 105 (44.5) 118 (50.6) 0.009
Grades 3–4 41 (17.4) 56 (24.0)
Infection
Grades 1–2 71 (30.1) 67 (28.8) 0.95
Grades 3–4 5 (2.1)
a 5 (2.1)
Anemia
Grades 1–2 95 (40.2) 93 (39.9) 0.60
Grade 3 3 (1.3) 1 (0.4)
Nausea-vomiting
Grades 1–2 150 (63.6) 151 (64.8) o0.0001
Grades 3–4 58 (24.6) 27 (11.6)
Stomatitis
Grades 1–2 85 (36.0) 49 (21.0) 0.0007
Grades 3 7 (3.0) 4 (1.7)
Diarrhoea
Grade 1–2 30 (12.7) 24 (10.3) 0.27
Grade 3 0 (0.0) 2 (0.9)
Alopecia
Grades 1–2 49 (20.8) 113 (48.5) o0.0001
Grade 3 160 (67.8) 64 (27.5)
Asthenia
Grades 1–2 47 (19.9) 38 (16.3) 0.14
Grade 3 5 (2.1) 1 (0.4)
Epi-Vnr¼epirubicin–vinorelbine.
aOne patient died from a septic shock.
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stubuline. On the other hand, a sequential treatment of FEC100
(three cycles) followed by docetaxel (three cycles) provided a
significant improvement in DFS and OS compared with six cycles
of FEC100 for node-positive breast cancer patients (Roche ´ et al,
2004). Thus, the best way to use vinorelbine in adjuvant setting
could be a sequential regimen with an anthracycline, as it has been
shown with docetaxel and paclitaxel (Henderson et al, 2003; Roche ´
et al, 2004; Mamounas et al, 2005; Crown et al, 2006). A recent trial
compared docetaxel and vinorelbine followed by FEC with or
without trastuzumab in node-positive or high-risk node-negative
early breast cancer patients (Joensuu et al, 2006). After 3 years of
follow-up, docetaxel significantly improved recurrence-free survi-
val compared to vinorelbine without improvement in survival.
Docetaxel was associated with more adverse events than vino-
relbine, and noteworthy, trastuzumab therapy did not lead to an
increase risk of LVEF decrease or CHF.
The Epi-Vnr regimen provided a similar efficacy to the classical
FEC100 regimen and could be an alternative option for node-
positive breast cancer patients. The choice of adjuvant chemo-
therapy should be based on safety and patient’s preferences.
Knowing the interest of sequential adjuvant chemotherapy, further
trials evaluating a regimen in which FEC100 was used sequentially
with vinorelbine as well as a direct comparison with a taxane-
based regimen could be of interest.
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